FDA accepts review of long-delayed Merck blood clot drug

[riky]

FDA accepts review of long-delayed Merck blood clot drug

(Adds Merck comment, share movement) By Ransdell Pierson July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke. The experimental drug, acquired by Merck through its 2009 acquisition of rival U.S. drugmaker Schering-Plough Corp., was once considered a potential blockbuster product. ...

Source: You are not allowed to view links. Register or Login